Exportin 1 (Chromosome Region Maintenance 1 Protein Homolog or XPO1) Drugs in Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Exportin 1 Pipeline Drugs Market Report Overview
Exportin 1 (XPO1) or chromosomal maintenance 1 (CRM1) is a eukaryotic protein. It mediates the nuclear export of cellular proteins bearing a leucine-rich nuclear export signal (NES) and of RNAs. In association with RANBP3, it binds cooperatively to the NES on its target protein and to the GTPase RAN in its active Ran-GTP. Docking of this complex to the nuclear pore complex (NPC) is mediated through binding to nucleoporins. It is involved in U3 snoRNA transport from Cajal bodies to nucleoli.
The Exportin 1 – Drugs in Development research report provides a comprehensive overview on the therapeutics under development for Exportin 1, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for XPO1 and features dormant and discontinued projects.
Key Therapy Areas in the Exportin 1 Pipeline Drugs Market
In the XPO1 pipeline drugs market the key therapy areas are Oncology, Central Nervous System, Immunology, Genetic Disorders, Infectious Disease, and Metabolic Disorders.
Exportin 1 Pipeline Drugs Market, by Therapy Areas
For more therapy areas insights, download a free report sample
Key MoA in the Exportin 1 Pipeline Drugs Market
The key MoA in the Exportin 1 pipeline drugs market is Exportin 1 Inhibitor.
Exportin 1 Pipeline Drugs Market Segmentation by RoA
The key routes of administration in the Exportin 1 pipeline drugs market are oral, and topical.
Exportin 1 Pipeline Drugs Market Analysis, by RoA
To get more insights on key RoA, download a free sample report
Key Molecule Types in the Exportin 1 Pipeline Drugs Market
The key molecule type in the Chromosomal Maintenance 1 pipeline drugs market is Small Molecule.
Major Companies in the Exportin 1 Pipeline Drugs Market
The major companies in the Exportin 1 pipeline drugs market are Karyopharm Therapeutics Inc, Wigen Biomedicine Technology (Shanghai) Co Ltd, Biogen Inc, CanBas Co Ltd, Jiangsu Carephar Pharmaceutical Co Ltd, and Oita University Institute of Advanced Medicine Inc.
Exportin 1 Pipeline Drugs Market, by Major Companies
For more company insights, download a free sample report
Exportin 1 Pipeline Drugs Market Overview
Key Therapy Areas | Oncology, Central Nervous System, Immunology, Genetic Disorders, Infectious Disease, and Metabolic Disorders |
Key Mechanisms of action | Exportin 1 Inhibitor |
Key Routes of Administration | Oral, and Topical |
Key Molecule Types | Small Molecule |
Major Companies | Karyopharm Therapeutics Inc, Wigen Biomedicine Technology (Shanghai) Co Ltd, Biogen Inc, CanBas Co Ltd, Jiangsu Carephar Pharmaceutical Co Ltd, and Oita University Institute of Advanced Medicine Inc |
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Exportin 1
- The pipeline guide reviews pipeline therapeutics for Exportin 1 by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Exportin 1 therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Exportin 1 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews the latest news related to pipeline therapeutics for Exportin 1
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counter strategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Exportin 1
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Exportin 1 pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
CanBas Co Ltd
Jiangsu Carephar Pharmaceutical Co Ltd
Karyopharm Therapeutics Inc
Oita University Institute of Advanced Medicine Inc
Wigen Biomedicine Technology (Shanghai) Co Ltd
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key therapy areas in the Exportin 1 pipeline drugs market?
In the Exportin 1 pipeline drugs market the key therapy areas are Oncology, Central Nervous System, Immunology, Genetic Disorders, Infectious Disease, and Metabolic Disorders.
-
What are the key mechanisms of action in the Exportin 1 pipeline drugs market?
In the Exportin 1 pipeline drugs market the key mechanism of action is Exportin 1 Inhibitor.
-
What are the key routes of administration in the Exportin 1 pipeline drugs market?
The key routes of administration in the Exportin 1 pipeline drugs market are Oral, and Topical.
-
What are the key molecule types in the Exportin 1 pipeline drugs market?
The key molecule type in the Exportin 1 pipeline drugs market is Small Molecule.
-
What are the major companies in the Exportin 1 pipeline drugs market?
In the Exportin 1 pipeline drugs market the major companies are Karyopharm Therapeutics Inc, Wigen Biomedicine Technology (Shanghai) Co Ltd, Biogen Inc, CanBas Co Ltd, Jiangsu Carephar Pharmaceutical Co Ltd, and Oita University Institute of Advanced Medicine Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Related reports
View more Other Diseases reports![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)
![](https://www.globaldata.com/store/wp-content/uploads/sites/2/blue_1bg2.webp)